Uncategorized Archives - Page 23 of 249

TuesdayMar 21, 2023 9:00 am

India Globalization Capital Inc. (NYSE American: IGC) Reports Triple-Digit Revenue Growth, Phase 2 Study Highlights in Q3 2023 Report

Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, the company reports Corporate highlights included expanded trial sites, enrollment for phase 2 IGC-AD1 study Commencement of study marks milestone in IGC’s progress toward gaining FDA approval for proprietary treatment In a fragile economic environment, the third-quarter 2023 financial results reported by India Globalization Capital (NYSE American: IGC) are particularly remarkable. The company, which is pursuing effective treatment for Alzheimer’s patients suffering with agitation and other neuropsychiatric symptoms, released a report showing an increase in net revenue of 133% for the three-month period ending Dec. 31,…

MondayMar 20, 2023 4:20 pm

420 with CNW — Florida House Committee Approves Bill Allowing Telehealth Medical Cannabis Certification

A Florida House Committee has unanimously approved a measure that would allow the use of telehealth in certain aspects of cannabis treatment. Bill HB 387 would make it possible for doctors to use telehealth to renew their patients’ medical cannabis approvals. According to sponsor Rep Spencer Roach, the bill would treat medical cannabis like any other pharmaceutical. Venice-based physician Dr. Barry Gordon told the House Health Care Regulation Subcommittee before the vote that leveraging telehealth to renew medical cannabis certifications would benefit the most vulnerable Floridians. As dozens of states have legalized marijuana for medical use, millions of people across…

TuesdayMar 14, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes

Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more With its unique product offering, a growing list of patents, and…

FridayMar 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Additional Findings From Human Clinical Study, Demonstrating DehydraTECH(TM)-CBD Effects on Hypertension

The global antihypertensive drugs market was valued at around $20.5 billion in 2021 and is expected to reach $39.5 billion by 2030, growing at a CAGR of 2.95% Lexaria’s patented DehydraTECH(TM) technology is designed to formulate and deliver lipophilic drugs and active pharmaceutical ingredients (“APIs”), increasing effectiveness and improving how drugs are delivered into the bloodstream DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, or oral suspensions Lexaria is continuing to evaluate the results of its HYPER-H21-4 human clinical study and will report additional findings as they become…

TuesdayMar 07, 2023 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase

Government showing strong support for bills aimed at treating Alzheimer’s disease IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2 Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease” Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://cnw.fm/xqOnK). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE American: IGC), a…

TuesdayMar 07, 2023 9:36 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms, Holds Discussions With Several Larger Companies on Path to Commercialization of DehydraTECH(TM) Technology

Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients The company out-licenses the use of its patented DehydraTECH(TM) technology within the pharmaceutical industry and consumer sectors Lexaria has focused on applied R&D to establish areas of investigation for commercial pursuits, with its programs proving successful Additionally, Lexaria has a robust intellectual property portfolio with 28 patents granted worldwide as of February 2023 In 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator developing and commercializing its…

FridayMar 03, 2023 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms

Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://cnw.fm/6qps2). The company is developing its…

ThursdayMar 02, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Disrupt Drug Delivery Through Innovation

Lexaria's DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its…

WednesdayMar 01, 2023 10:30 am

Prime Harvest Inc. Reveals That Their Reg A+ Equity Offering Has Been Granted Approval to Go Ahead

Prime Harvest recently revealed that the company’s Reg A+ equity offering has been greenlighted by the SEC The primary share offering will see the company market up to 10 million shares to investors at a price of $4.20 each, with estimated gross proceeds of $42 million The company has said that net proceeds will be destined towards the acquisition of licensed assets, continued expansion of their delivery network and general corporate purposes Prime Harvest, a technology-focused, full-service cannabis company based in San Diego, recently announced the qualification of its equity offering under the SEC’s Regulation A+. The offering, which has…

WednesdayMar 01, 2023 9:00 am

Explore all things cannabis at CannExpo March 25-26 at Enercare Centre

Toronto’s premiere destination for canna-curious and enthusiasts alike CannExpo Toronto, a consumer and retail cannabis show taking place March 24-26th, 2023 at the Enercare Centre, will feature three full days of exhibits and events for cannabis consumers, licensed retailers and budtenders. Visitors can discover new products and cutting edge technology, plus purchase accessories, hardware and services. Exhibitors include popular cannabis brands such as Slow Ride Bakery, Shatterizer and Weed Me Inc., Licensed Retail Stores including Canada’s first cannabis store owned by a Woman of Colour; GreenPort, craft growers, accessories, cannabis crafts, organic hemp products and more. The Ontario Cannabis Store…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

Category: Uncategorized